News & Media

Recent updates from Arcutis.

October 19, 2023

Arcutis Announces Pricing of $100 Million Public Offering

October 19, 2023

Arcutis Announces Proposed Public Offering

October 13, 2023

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

October 6, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

October 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 27, 2023

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

September 25, 2023

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

September 19, 2023

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 15, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2023

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 7, 2023

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 5, 2023

Arcutis to Present at Upcoming Investor Conference

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download